Peer-reviewed veterinary case report
Green lipped mussel and krill oil vs NSAIDs for dog arthritis pain
By Kampa, Naruepon et al.·Published in Frontiers in veterinary science·2024·Faculty of Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of the comparative efficacy of green lipped mussel plus krill oil extracts (EAB-277),extracts or NSAIDs for the treatment of dogs with osteoarthritis associated pain: a blinded, placebo-controlled study.
- Species:
- dog
Plain-English summary
A group of 101 dogs with hip pain from osteoarthritis were treated with either a green-lipped mussel and krill oil supplement (EAB-277), another supplement (4CYTE), a common pain medication (meloxicam), or a placebo. After six weeks, both the EAB-277 and meloxicam groups showed significant improvements in pain relief and mobility compared to the placebo and 4CYTE groups, which did not show any benefits. This suggests that EAB-277 and meloxicam are effective options for managing osteoarthritis pain in dogs.
People also search for: dog osteoarthritis treatment · green lipped mussel for dogs · meloxicam for dog pain
Abstract
INTRODUCTION: With little to no regulation of the supplement markets and a paucity of quality information regarding clinical utility of individual marketed supplements, it is difficult for veterinarians to provide any evidence-based recommendations to owners. The current study aimed to provide clinically useful comparative efficacy data on certain marketed supplements. METHODS: Using a prospective, block-randomized, double-blinded, placebo-controlled design, one hundred and one pet dogs with clinical hip OA-associated pain with one side worse than the other (index limb) were randomly assigned to one of four treatment groups: Green lipped Mussel plus Krill oil extracts (Antinol® Rapid, EAB-277);extracts (4CYTE™ Epiitalis® Forte); an NSAID (meloxicam); or placebo (sunflower oil). Peak vertical force (PVF, expressed as a percentage of bodyweight) of the index limb, orthopedic assessment score (OAS) and hematology and blood chemistry values were evaluated before treatment (week 0), at 2, 4 and 6 weeks during treatment. RESULTS: At 6 weeks, the changes from baseline in PVF of the index limb in the EAB-277 and meloxicam groups were significantly greater than the change in the placebo and 4CYTE™ groups, and the placebo and 4CYTE groups were not different from each other. At 6 weeks, there were significant differences between the groups for overall OAS scores with the lowest scores (least impairment) in the EAB-277 and meloxicam groups, followed by the 4CYTE group and then the placebo group. DISCUSSION: Results of this study indicate that meloxicam and EAB-277 have significant objectively measured benefits in managing OA-related pain in dogs compared to placebo, but 4CYTE does not differ from placebo.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39450405/